Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Non-Current Deffered Revenue (2016 - 2022)

Veracyte (VCYT) has disclosed Non-Current Deffered Revenue for 10 consecutive years, with $278000.0 as the latest value for Q1 2022.

  • Quarterly Non-Current Deffered Revenue fell 62.78% to $278000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $278000.0 through Mar 2022, down 62.78% year-over-year, with the annual reading at $343000.0 for FY2021, 58.62% down from the prior year.
  • Non-Current Deffered Revenue hit $278000.0 in Q1 2022 for Veracyte, down from $343000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $4.1 million in Q1 2018 to a low of $278000.0 in Q1 2022.
  • Historically, Non-Current Deffered Revenue has averaged $1.9 million across 4 years, with a median of $788000.0 in 2020.
  • Biggest five-year swings in Non-Current Deffered Revenue: dropped 6.36% in 2018 and later plummeted 62.78% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $3.9 million in 2018, then plummeted by 78.74% to $829000.0 in 2020, then tumbled by 58.62% to $343000.0 in 2021, then fell by 18.95% to $278000.0 in 2022.
  • Business Quant data shows Non-Current Deffered Revenue for VCYT at $278000.0 in Q1 2022, $343000.0 in Q4 2021, and $552000.0 in Q3 2021.